8086
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Nipro Corporation is a medical device and pharmaceutical manufacturer operating through three business segments: Medical, Pharmaceutical, and Pharma Packaging. The Medical segment develops and manufactures medical devices and materials, including products for hemodialysis and vascular access, under brands such as Avanteck Vascular and InfraredeX. The Pharmaceutical segment focuses on the production of pharmaceuticals and raw materials, with key operations through Nipro Pharma and Zen'ei Pharmaceutical. The Pharma Packaging segment supplies medical glass containers and packaging solutions via subsidiaries like Nipro Pharma Packaging International. The company serves global markets with a presence in Asia, Europe, and the Americas, utilizing subsidiaries in Japan, Vietnam, Thailand, Brazil, Belgium, the United States, Singapore, China, India, Indonesia, France, and Germany. Nipro Corporation maintains a strategic partnership with Spryte Medical Holdings, LLC, holding a significant equity stake in the US-based medical technology firm.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Medical Devices Homepage nipro.co.jp
Sector Healthcare IR page nipro.co.jp
Tags
hemodialysis, vascular access, pharmaceuticals, medical glass, pharma packaging, medical devices, healthcare infrastructure, Nipro Iko, Goodman, Nipro Vietnam Company Limited, Nipro Thailand Corporation, Nipro Medical Ltda, Nipro Medical Europe N.V., Nipro Medical Corporation, Nipro Asia Pte Ltd., Nipro Trading (Shanghai) Co. Ltd., Nipro India Corporation Private Limited, Nipro Medical Devices (Hefei) Co. Ltd., PT. Nipro Indonesia JAYA, Avanteck Vascular Corporation, InfraredeX Inc., Nipro Pharma, Zen'ei Pharmaceutical Industry Co. Ltd., Nipro Pharma Vietnam Limited, Nipro Pharma Packaging International N.V., Nipro Pharmaceutical Packaging Containers (Shanghai) Co. Ltd., Nipro Medical Packaging Materials (Anyang) Co. Ltd., Nipro Pharma Packaging India Private Limited, Nipro Pharma Packaging Americas Corp., Nipro Pharma Packaging France S.A.S., Nipro Pharma Packaging Germany GmbH, Nisho Insurance Travel Co. Ltd., Nipro Europe Group Companies N.V., Nipro Digital Technologies Europe N.V., Nipro (China) Investment Co. Ltd., Nipro Americas Group Companies Inc., Spryte Medical Holdings LLC
Press page nipro.co.jp/ir/news

Metrics

Valuation  
Market cap ¥ 253.268B
Market cap (USD) $ 1.587B
P/E 20.71
PEG 0.48
P/BV 0.68
P/S 0.37
P/OCF 5.07
P/FCF -11.83
Dividend yield 2.1%
Turnover / mcap —
Returns  
ROE 4.2%
ROI 1.7%
ROIC 2.5%
Profit margin 2.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 43.5%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 3
Quality score 5.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 660.538B 644.586B 586.785B 545.199B 494.789B 455.559B 442.516B 426.399B 395.397B 359.699B 366.65B 325.084B 300.752B 241.02B
Net profit 13.504B 5.113B 11.109B 4.574B 13.455B 14.209B -12.281B 12.136B 11.829B 11.346B 19.718B 12.47B 2.861B 10.231B
Free cash flow -7.634B -8.133B -21.267B -74.44B -11.589B 14.911B -20.697B -14.618B -21.336B -30.674B -12.002B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.552K 1.359K 1.226K 1.019K 1.024K 1.337K 1.429K 1.429K 1.537K 1.57K 1.069K 1.145K 926.83 836.83
Price performance 12m 0.14 0.11 0.2 -0 -0.23 -0.06 0 -0.07 -0.02 0.47 -0.07 0.24 0.11 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 121B 141B 149B 152B 141B 281B 321B 320B 334B 351B
↳ YoY growth +6.9% +16.1% +6.0% +2.3% -7.8% +99.7% +14.2% 0.0% +4.1% +5.3%
↳ 5y CAGR +4.4% +18.3% +17.9% +16.6% +17.0% +20.1%
Borrowings, current (JPY) 143B 129B 143B 137B 136B 153B 143B 185B 157B 197B
Borrowings, non-current (JPY) 311B 381B 386B 360B 370B 377B 423B 415B 443B 383B
Bonds payable (JPY) 45.4B 31.2B 40B 29.1B 77.5B 111B 109B 117B 134B 104B
Lease liabilities (JPY) 3.98B 3.74B 6.73B 13.2B 32.1B 29.5B 29.7B 30.1B 31.8B 28.6B
Cash and deposits (JPY) 123B 142B 129B 95.9B 90.3B 95.3B 89.7B 99.7B 107B 97.8B
Intangible assets (JPY) 43.8B 46B 39.4B 33.4B 29.8B 32.8B 34B 35.1B 35.5B 51.7B
Net debt (borrowings + leases - cash) (JPY) 335B 371B 406B 415B 448B 464B 506B 530B 525B 510B
Cash flow detail
Operating cash flow (JPY) 33.5B 41B 41.4B 37.2B 66.1B 68.2B 10.4B 72.9B 68.5B 54.7B
Purchases of property, plant and equipment (JPY) -64.1B -62.4B -56B -57.9B -51.2B -79.8B -84.8B -94.2B -76.6B -62.3B
Change in receivables (cash effect) (JPY) -9.32B -7.33B -12.3B -2.65B 10.5B 6.66B -11.1B 7.85B 2.08B -3.77B
Change in inventories (cash effect) (JPY) -17.7B -4.9B -11.4B -15.2B -12.9B -7.94B -25B -13.8B -17.3B -9.69B
Change in payables (cash effect) (JPY) 4.58B -3.82B 11.8B 205M -567M 704M -5.78B 272M -2.58B -1.97B
Dividends paid (cash effect) (JPY) -4.07B -6.48B -4.95B -3.66B -1.72B -5.22B -4.25B -3.03B -4.41B -3.76B
Share buybacks (cash effect) (JPY) -5B -1M -5B -8M -699M -2M -1M -34M -7M -17M
Interest paid (cash effect) (JPY) -3.91B -3.3B -3.21B -3.2B -3.87B -3.98B -4.25B -6.27B -7.83B -9.28B
Income taxes paid (cash effect) (JPY) -7.31B -7.33B -8.18B -9.11B -7.07B -6.09B -9.57B -9.07B -13.2B -10.4B
Operating cash flow before change in receivables (JPY) 42.8B 48.4B 53.6B 39.9B 55.6B 61.6B 21.5B 65.1B 66.4B 58.4B
Free cash flow (OCF - PPE - intangibles) (JPY) -30.7B -21.3B -14.6B -20.7B 14.9B -11.6B -74.4B -21.3B -8.13B -7.63B
Income detail
Research and development expense (JPY) 11.5B 16.1B 16.5B 18.2B 18.7B 18.7B 19.7B 20.8B 21.7B 26.8B
↳ 5y CAGR +12.7% +10.2% +4.1% +4.8% +3.5% +7.5%
Total comprehensive income (JPY) 10.8B 13.5B -1.84B -8.85B 14.8B 32B 26B 29.9B 26.3B 27.3B
Comprehensive income to owners (JPY) 10.8B 13B -1.32B -9.04B 13.8B 30B 24.8B 28.7B 24.4B 25.2B
Provision for credit losses (JPY) 303M 157M 187M 610M 3.02B 1.15B 1.58B 1.65B 1.99B 990M
Credit cost ratio (credit losses / average receivables) (%) 0.3% 0.1% 0.1% 0.4% 2.1% 0.5% 0.5% 0.5% 0.6% 0.3%
Segments
Pharma Packaging · Segment revenue (JPY) 28.3B 28.5B 40.6B 41.9B 44.8B 52.5B 57.7B 64.3B 66.1B 62B
↳ YoY growth -14.3% +0.5% +42.7% +3.1% +7.0% +17.2% +10.0% +11.4% +2.8% -6.2%
Pharma Packaging · Segment operating income (JPY) -1.31B -1.31B 778M 675M 1.99B 2.89B 2.74B 2.45B -272M -1.59B
Reported Jun 28, 2017 Jun 27, 2018 Jun 26, 2019 Jun 26, 2020 Jun 30, 2021 Jun 28, 2022 Jun 28, 2023 Jun 26, 2024 Jun 25, 2025 Jun 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Nipro Corporation (ticker 8086), listed in Japan.

ETFs Holding Nipro Corporation

ETF Weight in ETF Shares Market value As of
AVDV 0.21% 4,694,700 $ 41.643M Nov 16, 2026
DISV 0.09% 534,300 $ 4.558M Nov 12, 2026
AVDS 0.06% 24,600 $ 218.209K Nov 16, 2026
DFIS 0.05% 341,400 $ 2.912M Nov 12, 2026
AVSD 0.03% 13,300 $ 117.975K Nov 16, 2026
DFIC 0.02% 368,406 $ 3.143M Nov 12, 2026
AVDE 0.02% 364,000 $ 3.229M Nov 16, 2026
DXIV 0.02% 5,600 $ 47.77K Nov 12, 2026
DFAX 0.01% 144,700 $ 1.234M Nov 12, 2026
DFAI 0.01% 160,594 $ 1.37M Nov 12, 2026